Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02865135 · ClinicalTrials.gov registry record · Phase 1
Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
A Phase 1 study of Cancer of Head and Neck and Cancer of Cervix, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT02865135: Completed Phase 1 study of Cancer of Head and Neck and Cancer of Cervix, sponsored by Dana-Farber Cancer Institute.
NCT02865135 is a Phase 1 study of Cancer of Head and Neck and Cancer of Cervix that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 11 participants, below the 248-participant average among 9 other Cancer of Head and Neck trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02865135, a Phase 1 study of Cancer of Head and Neck and Cancer of Cervix, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying a therapeutic vaccine, named DPX-E7, as a possible treatment for Human Papilloma Virus or HPV related head and neck, cervical or anal cancer (positive for HLA-A\*02).
Primary Outcome
A DLT was defined as any grade 3 or greater adverse event at least possibly related to the study agent including injection site reactions; or grade 2 or greater allergic reactions which occur in a subject prior to day 50, will trigger DLT. In addition, to be considered as DLT, the adverse event must be considered at least possibly related to study treatment. Grade 3 or greater abnormal lab values lasting \<= 72 hours might be excluded as DLTs if there are no accompanying clinical signs and sympt
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG DPX-E7 vaccine
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-03-30 |
| Est. Completion | 2023-02-06 |
| Phase | Phase 1 |
What the finished NCT02865135 record still lists
NCT02865135 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 248-participant average among 9 other Cancer of Head and Neck trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Cancer of Head and Neck appearing as the primary indexed condition, and to 2 interventions - of which Cyclophosphamide is the first listed.
NCT02865135 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02865135 about?
NCT02865135 is a clinical study titled "Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer". This research study is studying a therapeutic vaccine, named DPX-E7, as a possible treatment for Human Papilloma Virus or HPV related head and neck, cervical or anal cancer (positive for HLA-A\*02).
What is the current status of trial NCT02865135?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2017-03-30. Estimated completion is 2023-02-06.
What conditions does trial NCT02865135 study?
This clinical trial studies the following conditions: Cancer of Head and Neck, Cancer of Cervix, Cancer of Anus.
What interventions are being tested in trial NCT02865135?
The interventions under investigation include: Cyclophosphamide (DRUG), DPX-E7 vaccine (DRUG).
Who is sponsoring clinical trial NCT02865135?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02865135 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer of Head and Neck
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02865135's enrollment target sits among peer trials
11 7th of 9 higher than 2 of 9 other Cancer of Head and Neck trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer of Head and Neck trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Multicenter Cancer Biospecimen Collection Study
RECRUITING
-
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Comprehensive Approach to Head and Neck Cancer Prehabilitation
ACTIVE NOT RECRUITING · NA
-
Onco-primary Care Networking to Support TEAM-based Care
ACTIVE NOT RECRUITING · NA
-
Adaptive Radiation Therapy for Head & Neck Cancer Patients
COMPLETED · NA
-
The Gut Microbiome As an Indicator of Readiness for Head & Neck Cancer Surgery
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI